Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 22 December, 2024
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 524663 | NSE: BIBCL

Bharat Immunological & Biological Corporation Ltd: Fundamental Analysis, Share Price Insights & Intrinsic Value (2024)

Share Price and Basic Stock Data

Last Updated: December 21, 2024, 1:18 am

Market Cap 101 Cr.
Current Price 23.4
High / Low 43.9/22.2
Stock P/E
Book Value 18.2
Dividend Yield0.00 %
ROCE9.27 %
ROE17.7 %
Face Value 10.0
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for

Competitors of

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Gujarat Themis Biosyn Ltd 3,354 Cr. 308 390/12863.6 20.50.22 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 62.6 Cr. 84.4 94.9/26.624.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 35.9 Cr. 24.5 24.5/8.7446.6 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 86.7 Cr. 115 155/87.013.0 55.40.00 %14.4 %15.5 % 10.0
Glenmark Life Sciences Ltd 12,416 Cr. 1,013 1,335/64529.3 2072.22 %28.1 %21.1 % 2.00
Industry Average19,016.52 Cr1,181.3156.05186.300.32%16.20%16.32%6.27

All Competitor Stocks of

Quarterly Result

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales25.3625.2015.6214.2224.7017.4322.0410.4826.480.007.650.000.00
Expenses29.8627.4731.5413.1828.1916.4125.7115.3128.984.7211.674.314.68
Operating Profit-4.50-2.27-15.921.04-3.491.02-3.67-4.83-2.50-4.72-4.02-4.31-4.68
OPM %-17.74%-9.01%-101.92%7.31%-14.13%5.85%-16.65%-46.09%-9.44%-52.55%
Other Income0.141.209.080.250.220.120.590.140.320.100.490.100.16
Interest1.171.301.221.161.231.541.681.581.741.672.061.722.09
Depreciation0.060.060.060.060.060.040.050.040.040.040.090.030.03
Profit before tax-5.59-2.43-8.120.07-4.56-0.44-4.81-6.31-3.96-6.33-5.68-5.96-6.64
Tax %-30.77%-21.81%-19.46%-2,642.86%105.26%-25.00%-11.02%-20.76%-22.22%-26.07%-31.69%-23.15%-26.05%
Net Profit-3.87-1.89-6.531.93-9.36-0.33-4.28-5.00-3.08-4.68-3.88-4.59-4.92
EPS in Rs-0.90-0.44-1.510.45-2.17-0.08-0.99-1.16-0.71-1.08-0.90-1.06-1.14

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales461732031461281243584678578458
Expenses41164191143132111439377106836325
Operating Profit69123-413-8-9-10-21-5-18-18
OPM %12%5%6%2%-3%10%-23%-11%-16%-24%-6%-41%-232%
Other Income2161111412131
Interest0261641255678
Depreciation1111110000000
Profit before tax67112-99-8-7-14-24-10-23-25
Tax %-111%27%42%26%-31%29%-46%-21%-28%-25%-10%-25%
Net Profit13562-67-4-6-10-18-9-17-18
EPS in Rs2.911.161.480.36-1.441.51-0.99-1.34-2.36-4.19-2.03-3.95-4.18
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)-61.54%20.00%-66.67%-400.00%216.67%-157.14%-50.00%-66.67%-80.00%50.00%-88.89%
Change in YoY Net Profit Growth (%)0.00%81.54%-86.67%-333.33%616.67%-373.81%107.14%-16.67%-13.33%130.00%-138.89%

has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:-13%
5 Years:5%
3 Years:-13%
TTM:-90%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:-31%
TTM:-42%
Stock Price CAGR
10 Years:-4%
5 Years:25%
3 Years:-21%
1 Year:-43%
Return on Equity
10 Years:-12%
5 Years:-24%
3 Years:-23%
Last Year:-18%

Last Updated: Unknown

Balance Sheet

Last Updated: Unknown

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital43434343434343434343434343
Reserves-15-1-3-2-8-1-6-12-23-9624536
Borrowings70-1-990032327787074
Other Liabilities454852482417166210343292835
Total Liabilities81909180685953125127104213186188
Fixed Assets9876655544116115115
CWIP10000000032000
Investments0000000000000
Other Assets7182847463534812012268977073
Total Assets81909180685953125127104213186188

Reserves and Borrowings Chart

Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity +531-128-9-173-323412-4211
Cash from Investing Activity +-000010-111110
Cash from Financing Activity +-3-0-6-1-2-3-131-34-1245-15
Net Cash Flow231-187-10-201-1103-3

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow-1.009.0013.0012.00-13.0013.00-8.00-41.00-13.00-48.00-83.00-88.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days2092473437191673189605114
Inventory Days24187668477223673085620213
Days Payable316997010326162042596154
Cash Conversion Cycle134-943168819185181145-5203122
Working Capital Days34-2019-255-1959151-91-5713525
ROCE %20%23%42%9%-8%31%-18%-11%-22%-46%-3%-9%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Promoters59.25%59.25%59.25%59.25%59.25%59.25%59.25%59.25%59.25%59.25%59.25%59.25%
Public40.75%40.75%40.75%40.75%40.75%40.75%40.75%40.74%40.74%40.75%40.75%40.74%
No. of Shareholders38,19536,79936,86936,32335,69535,44236,24235,55034,81834,20134,91035,313

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)-3.95-2.03-4.19-2.36-1.57
Diluted EPS (Rs.)-3.95-2.03-4.19-2.36-1.57
Cash EPS (Rs.)-3.92-1.98-4.14-2.31-1.28
Book Value[Excl.RevalReserv]/Share (Rs.)20.3324.407.884.747.10
Book Value[Incl.RevalReserv]/Share (Rs.)20.3324.407.884.747.10
Revenue From Operations / Share (Rs.)10.3318.1519.7615.4819.37
PBDIT / Share (Rs.)-3.63-0.89-4.45-2.14-1.18
PBIT / Share (Rs.)-3.66-0.94-4.50-2.19-1.24
PBT / Share (Rs.)-5.29-2.24-5.61-3.29-1.71
Net Profit / Share (Rs.)-3.95-2.03-4.19-2.36-1.34
PBDIT Margin (%)-35.11-4.95-22.49-13.80-6.08
PBIT Margin (%)-35.44-5.22-22.76-14.15-6.41
PBT Margin (%)-51.22-12.35-28.36-21.25-8.81
Net Profit Margin (%)-38.23-11.16-21.22-15.27-6.92
Return on Networth / Equity (%)-19.42-8.30-53.20-49.87-18.88
Return on Capital Employeed (%)-16.78-3.67-48.70-36.22-14.71
Return On Assets (%)-9.18-4.11-17.41-8.05-4.63
Total Debt / Equity (X)0.790.730.800.141.05
Asset Turnover Ratio (%)0.220.490.730.530.93
Current Ratio (X)0.360.640.520.921.12
Quick Ratio (X)0.340.280.310.410.95
Inventory Turnover Ratio (X)1.752.381.872.0810.43
Interest Coverage Ratio (X)-2.22-0.69-4.02-1.95-2.54
Interest Coverage Ratio (Post Tax) (X)-1.42-0.56-2.79-1.15-1.89
Enterprise Value (Cr.)157.30186.21213.2316.0757.50
EV / Net Operating Revenue (X)3.532.382.500.240.68
EV / EBITDA (X)-10.04-47.96-11.11-1.74-11.29
MarketCap / Net Operating Revenue (X)2.151.552.300.370.39
Price / BV (X)1.091.155.771.231.08
Price / Net Operating Revenue (X)2.151.552.300.370.39
EarningsYield-0.17-0.07-0.09-0.40-0.17

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of as of December 22, 2024 is: 49.29

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of December 22, 2024, is Undervalued by 110.64% compared to the current share price 23.40

Default values used*: Default value of 15 for Stock P/E is used

Intrinsic Value of as of December 22, 2024 is: 40.06

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of December 22, 2024, is Undervalued by 71.20% compared to the current share price 23.40

Default values used*: Default value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -18.73%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a low average Working Capital Days of 24.08, which is a positive sign.
  1. The stock has a low average ROCE of 0.67%, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 93.50, which may not be favorable.
  3. The company has higher borrowings (22.31) compared to reserves (4.85), which may suggest financial risk.
  4. The company has not shown consistent growth in sales (94.00) and profit (-6.54).
  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in :
    1. Net Profit Margin: -38.23%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: -16.78% (Industry Average ROCE: 16.2%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: -19.42% (Industry Average ROE: 16.32%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): -1.42
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.34
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 0 (Industry average Stock P/E: 56.05)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.79
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Bharat Immunological & Biologicals Corporation Ltd. is a Public Limited Listed company incorporated on 10/03/1989 and has its registered office in the State of Uttar Pradesh, India. Company’s Corporate Identification Number(CIN) is L24232UP1989GOI010542 and registration number is 010542. Currently company belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 78.39 Cr. and Equity Capital is Rs. 43.18 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsBIBCOL, OPV Plant, Village Chola, Bulandshahar Dist Uttar Pradesh 203203complianceofficer_bibcol@yahoo.in
http://www.bibcol.com
Management
NamePosition Held
Dr. Y K GuptaChairman
Dr. Sanjay Kumar MishraManaging Director
Dr. Alka SharmaDirector
Dr. Mohd AslamDirector
Mr. Roshan LalDirector
Dr. Sudhanshu VratiDirector
Dr. Madhu DikshitDirector

FAQ

What is the latest intrinsic value of ?

The latest intrinsic value of as on 21 December 2024 is ₹49.29, which is 110.64% higher than the current market price of ₹23.40. The stock has a market capitalization of 101 Cr. and recorded a high/low of 43.9/22.2 during the current fiscal year 2024-2025. As of Sep 2023, the company has reserves of ₹36 Cr and total liabilities of ₹188 Cr.

What is the Market Cap of ?

The Market Cap of is 101 Cr..

What is the current Stock Price of as on 21 December 2024?

The current stock price of as on 21 December 2024 is 23.4.

What is the High / Low of stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of stocks is 43.9/22.2.

What is the Stock P/E of ?

The Stock P/E of is .

What is the Book Value of ?

The Book Value of is 18.2.

What is the Dividend Yield of ?

The Dividend Yield of is 0.00 %.

What is the ROCE of ?

The ROCE of is 9.27 %.

What is the ROE of ?

The ROE of is 17.7 %.

What is the Face Value of ?

The Face Value of is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in . Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE